Book chapters will be unavailable on Saturday 24th August between 8am-12pm BST. This is for essential maintenance which will provide improved performance going forwards. Please accept our apologies for any inconvenience caused.
2.HenneyHR, RunyanDJ. A clinically relevant review of Tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and dose effectiveness in healthy subjects and patients. Int J Clin Pract2008;62(2):314–324.
3.WagstaffAJ, BrysonHM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs1997;53(3):435–452.
4.NancePW, SheremataWA, LynchSG, et al. Relationship of the antispasticity effect of Tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol1997;54:731–736.
5.Chou, et al. J Pain Symptom Manage2004;28(2):141–175.